Study details
Enrolling now
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
Baylor College of Medicine
NCT IDNCT02291848ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
36
Study length
about 13 years
Ages
18+
Locations
3 sites in TX
What this study is about
This trial is testing a new treatment called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes (CTLs) in people with multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), or smoldering myeloma. The goal is to find the safest dose and understand any side effects that might occur.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive TAA-specific CTLs
- 2.Receive TAA-specific CTLs- fixed dose
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Number of Patients with Adverse events
Body systems
Oncology